Science Amarin Investors Need to Know

Amarin's (Nasdaq: AMRN  ) new triglyceride-lowering drug, Vascepa, could have major advantages for patients over its main competitor -- GlaxoSmithKline's (NYSE: GSK  ) Lovaza -- since one of Lovaza's components has been associated with increasing LDL cholesterol, more commonly referred to as "bad" cholesterol. That could translate to major profits for Amarin should Vascepa reach the market, but the stock has stumbled recently due to delays in getting the NCE, or New Chemical Entity, status from the Food and Drug Administration. That has been tricky to get, since the main component of Vascepa is in fact part of Lovaza. In this video, Motley Fool health care analyst Max Macaluso sheds some light on why the FDA hasn't decided on Vascepa's status yet and what investors need to know going forward.

The biotech space can make or break investors ovnight, and while Amarin might not disappear into thin air, Vascepa's FDA status and the decisions the company makes in commercializing it will be key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top analyst Max Macaluso's premium research report. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2105076, ~/Articles/ArticleHandler.aspx, 10/26/2016 1:54:26 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 4 hours ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 4:00 PM
AMRN $3.29 Down +0.00 +0.00%
Amarin CAPS Rating: ****
GSK $40.32 Down -0.36 -0.88%
GlaxoSmithKline CAPS Rating: ***